| Hans-Günter Meyer-Thompson | HIV
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Bart G, Jaber M, Giang LM, Brundage RC, Korthuis PT.
Drug Alcohol Depend. 2022 Nov 11;241:109696. doi: 10.1016/j.drugalcdep.2022.109696. Epub ahead of print. PMID: 36402052.
Conclusions: (…) These findings indicate reduced buprenorphine bioavailability in patients with HIV.
Abstract